Switching Imids: The Optimismm Trials Impact On Mm | Latest News RSS feed

Switching Imids: The Optimismm Trials Impact On Mm - Latest News

An Assessment Of Celgene's Deal For Receptos

How ozanimod fits into Celgene's business plan Celgene's main products, namely Revlimid and the other IMiDs, are immuno-oncology products ... However, efficacy in MS was substantial in the Phase 2 ... read more

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems ... Twenty-four patients (32%) were refractory to IMIDs (Table 1). Response. ... read more

Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

sequencing using data from The Connect ® MM Patient Registry. (Jagannath) Relapsed/Refractory Multiple Myeloma Abstract #S847; Oral; Saturday, June 16, 16:00 – 16:15, Room A1. OPTIMISMM: Phase III ... read more

Looking for another news?

Current Challenges in the Management of Patients with Relapsed/Refractory Multiple Myeloma: Page 2 of 2

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma ... of a phase 2 trial in patients with relapsed and ... read more

Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and ...

The CHMP positive opinion for PVd was based on the data from OPTIMISMM, the first prospective ... in CLL outside of controlled clinical trials Second Primary Malignancies (SPM): In clinical trials in ... read more

Treating Multiple Myeloma at First Relapse

More recently, we have data from the OPTIMISMM trial that suggest pomalidomide can be partnered ... cells can become resistant to IMiDs. We see that with lenalidomide, we see that with pomalidomide, ... read more

Insights on Multiple Myeloma Treatment Strategies

1–3 The increase in available therapies and the development of others has led to an exponential growth in clinical trial data and a ... In relapsed/refractory MM, recommended treatment strategy ... read more

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

Our summary shows that there are very few data from current trials ... with MM 1,2. With the availability of at least 6 different classes of approved agents, i.e., alkylators, steroids, proteasome ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us